Cangrelor is a P2Y12 receptor antagonist with a specific clinical niche over oral P2Y12 inhibitors like ticagrelor. Its key advantage is:
- A IV administration with rapid onset and offset (half-life ~3–5 minutes) allowing precise antiplatelet control perioperatively ✓
- B Irreversible receptor binding providing sustained antiplatelet effect
- C Superior efficacy to prasugrel in high-risk ACS patients
- D Being active without requiring hepatic metabolic activation
Explanation
Cangrelor is an IV, reversible, direct-acting P2Y12 receptor antagonist with an extremely short half-life of 3–5 minutes. This pharmacokinetic profile provides near-immediate platelet inhibition upon infusion and rapid (30–60 minute) recovery of platelet function after discontinuation. This makes it ideal in bridging situations — e.g., when a patient on oral P2Y12 inhibitors requires urgent surgery, cangrelor can replace oral therapy and be stopped just before the procedure. Ticagrelor and clopidogrel require hours to days for platelet function recovery after stopping.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.